Compare ABRDN Physical Gold Shares ETF (SGOL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Sanofi SA — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 13.5× ABRDN Physical Gold Shares ETF's market cap, and Sanofi SA pays a 6.01% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Sanofi SA for 94 Days on average.
| SGOL | SNY | |
|---|---|---|
Market Cap | $7.03B | $95.18B |
Volume | 2,350,550 | 2,995,646 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $52.34 |
52-Week Low | $37.54 | $39.51 |
Typical Hold Time | 57 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.31, up 0.74% today, while technical indicators show a bearish bias with moving averages and ADX signaling sell conditions. The stock lacks key financial ratio data such as P/E and P/B, limiting fundamental clarity. Recent gold-related news highlights pressure from rising Treasury yields and a firm dollar, though softer inflation data has provided some support.
The outlook remains cautious due to macroeconomic headwinds and incomplete financial disclosures. Risks include interest rate sensitivity and gold price volatility. Investors should seek updated SEC filings for fundamental metrics before considering a position.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
